Can a pill get into brain tumors? tiny study aims to find out

NCT ID NCT05413304

Ongoing Knowledge-focused Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests whether the drug abemaciclib can be measured inside brain tumors after being taken by mouth. One person aged 18–39 with a recurrent high-grade glioma or diffuse midline glioma will take the drug for 4.5 days before surgery. During surgery, a small tube is placed in the brain to collect fluid samples for 48 hours, allowing researchers to see how much drug reaches the tumor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abemaciclib
What this could lead to: If successful, this could show whether abemaciclib reaches brain tumors effectively, guiding future treatment for these aggressive cancers.
What could go wrong: This is a tiny, early feasibility study with only 1 participant. It cannot prove the drug works, only that drug levels can be measured. Many such studies do not lead to effective treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE MIDLINE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer diffuse intrinsic pontine glioma glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.